Attention-deficit/hyperactivity dis...

Attention-deficit/hyperactivity disorder (ADHD) has protracted been treated with the stimulant medication methylphenidate in an immediate-release formula. The disadvantage of this medication is the to a high degree short half-life and the necessity for multiple dosing during the day. This becomes an issue when the medication is used to treat school-aged children. The optimal dosing schedule is three times in a 12-hour period, which would require that the medication be administered during seminary hours. This may cause embarrassment for the scholar and also has implications with regard to administering a controll substance during denomination hours. An initial attempt to create sustained-release methylphenidate was ill-starred because the formula reduced the effectiveness of the medication. lately however, a new sustained-release formula has been make knowned Swanson and colleagues studied the pharmacokinetics and pharmacodynamics of methylphenidate in the recent sustained-released formula.

The application of mind participants were children seven to 13 years of age who met criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV) for the diagnosis of ADHD. In addition, these children were already being treated with immediate-release methylphenidate in a dosage of 5 to 15 mg sum of two units to three times per day. A university laboratory gymnasium evaluated the children multiple times upon nonconsecutive days using a teachers' assessment tool. In the first phase of the meditation children were given capsules containing active medication or placebo in 30-minute intervals to determine the validity of a sustained-release preparation. In the secondary phase, the pharmacokinetics and pharmacodynamics of a of recent origin once-a-day methylphenidate were assessed.

The first phase of the thought demonstrated that the ascending dose that mirrored a sustained-release preparation was similar to the standard three-times-per-day dosage of methylphenidate. In the pharmacokinetic consideration of the new once-a-day formula of methylphenidate, plasma on a levels increased rapidly, peaking seven to nine hours after administration. The issues of the pharmacodynamic studies of the recent formula matched those of the three-times-per-day dosage of methylphenidate in spells of onset and duration of efficacy.

The authors finish that the new once-a-day formula of methylphenidate has a rapid assault and long duration of efficacy after a single morning dose. This provides children with ADHD an option for once-a-day treatment of their symptoms.

Swanson J et al. progression in a continuously ascending gradation of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry February 2003;60:204-11

COPYRIGHT 2003 American Academy of Family Physicians

COPYRIGHT 2003 Gale Group